Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer  Demonstration of Cyclin E1 protein overexpression as an ...

The finding suggests other chemo drugs, too, may be making cancer cells cause a surprising immune-system reaction.

Scientists have engineered a common probiotic bacterium to act like a microscopic drug factory that hunts down tumors and delivers cancer-killing compounds directly where they’re needed. Credit: ...

A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...

Danie van der LithA GROUNDBREAKING health initiative at the Cape Town Cycle Tour Expo has potentially saved 20 lives after detecting malignant melanoma in unsuspecting participants during free on-site ...

YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the ...

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...

A growing field of research suggests that some medical treatments, such as cancer therapy or vaccines, might be more ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...

A metabolic enzyme studied for over seven decades has a hidden second function - it can unwind RNA and promote cell cycle progression, an additional function beyond its role in energy production, ...